Evoke Pharma

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Results demonstrate continued increased awareness and intent to prescribe GIMOTI Results demonstrate continued increased awareness and intent to prescribe GIMOTI

Evoke Pharma and EVERSANA Announce Positive Findings from Second GIMOTI® Market Research Study

SOLANA BEACH, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its US patent No. 11,020,361 for Gimoti® (metoclopramide) nasal spray is now listed in the U.S. Food and Drug Administration (FDA) publication, “Approved Drug Products with Therapeutic Equivalence Evaluations”, commonly known as the “Orange Book”. The patent covers methods of use for nasal delivery of metoclopramide for the treatment of gastroparesis.

Evoke Pharma Announces FDA Orange Book Listing of U.S. Patent for Gimoti®

Evoke is committed to meeting patients online, where they search for answers

Evoke Pharma and EVERSANA Launch Social Media Campaign for Gimoti® Nasal Spray

SOLANA BEACH, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the appointment of Vickie Reed to the Company's board of directors. After serving for more than eight years on the Company's board, Ann Rhoads has announced her retirement.

Evoke Pharma Appoints Vickie Reed to Board of Directors

The stock price of Evoke Pharma Inc (NASDAQ: EVOK) fell by over 19% pre-market. This is why it happened.

Evoke Pharma (EVOK): Over 19% Decrease Pre-Market Explanation

Evoke Pharma, Inc. (EVOK) CEO David Gonyer on Q1 2021 Results - Earnings Call Transcript

Nearly 293% growth of product sales, 235% growth of prescriptions and 87% increase in new prescribers for Gimoti ®

Evoke Pharma Reports First Quarter 2021 Financial Results

SOLANA BEACH, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its first quarter 2021 financial results on Wednesday, May 12, 2021, after the market closes.

Evoke Pharma to Report First Quarter 2021 Financial Results on May 12, 2021

New patent expands intellectual property protection for nasal delivery of metoclopramide New patent expands intellectual property protection for nasal delivery of metoclopramide

Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a Method of Use Patent with Claims Covering Gimoti®

SOLANA BEACH, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a commercial stage specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that Yale Jen, Senior Biotech Analyst at Laidlaw & Company will host a fireside chat on Thursday, April 1, 2021, at 1:00pm ET with Dr. Kostas Sideridis, DO, an early adopter of GIMOTI and co-founder of Long Island Gastro, and Dr. Richard McCallum, MD, Division of Gastroenterology, Center for Neurogastroenterology and GI Motility, Texas Tech University Health Sciences Center El Paso.

Evoke Pharma Announces a Fireside Chat with Key Opinion Leaders on the Treatment of Gastroparesis

Altimmune

ContraFect

Novavax

Among the health care stock movers Friday are ContraFect Corporation (NASDAQ: CFRX), Evoke Pharma, Inc. (NASDAQ: EVOK), Altimmune, Inc. (NASDAQ: ALT) and Novavax, Inc. (NASDAQ: NVAX). Here's why the stocks are moving.

Why ContraFect, Evoke, Altimmune, Novavax Are Moving Friday

Evoke Pharma, Inc. (EVOK) CEO Dave Gonyer on Q4 2020 Results - Earnings Call Transcript

Evoke Pharma, Inc. (EVOK) delivered earnings and revenue surprises of -125.00% and -98.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Evoke Pharma, Inc. (EVOK) Reports Q4 Loss, Misses Revenue Estimates

SOLANA BEACH, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its fourth quarter and full year 2020 financial results on Thursday, March 11, 2021, after the market closes.

Evoke Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021

Evoke Pharma finally received FDA approval for Gimoti, a nasal formulation of a generic GI drug, in June 2020 and launched the drug in October 2020. Post-approval, the stock price decreased as investors' dreams of the company being acquired faded, and the reality of a small company drug launch became the story.

Evoke Pharma: Opportunity For Upside As Gimoti Sales Ramp

SOLANA BEACH, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, announced today the completion of its follow-on offering of 5,750,000 shares of its common stock, including 750,000 shares of common stock sold pursuant to the underwriter's full exercise of its option to purchase additional shares, at a price to the public of $2.50 per share. The gross proceeds from the offering were approximately $14.4 million, before underwriting discounts and commissions and estimated offering costs.

Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares

SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $2.50 per share. Gross proceeds, before underwriting discounts and commissions and estimated offering costs, are expected to be $12.5 million. Evoke has granted the underwriter a 45-day option to purchase up to 750,000 additional shares of its common stock. The offering is expected to close on or about January 19, 2021, subject to satisfaction of customary closing conditions.

Evoke Pharma Announces Pricing of Public Offering of Common Stock

SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it intends to offer and sell shares of its common stock in a “firm commitment” underwritten public offering. Evoke also expects to grant to the underwriter for the offering a 45-day option to purchase an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. All of the shares to be sold in the offering are to be sold by Evoke. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Evoke Pharma Announces Proposed Public Offering of Common Stock

Healthcare practitioner survey indicates physicians' awareness and intent to prescribe newly-launched product Healthcare practitioner survey indicates physicians' awareness and intent to prescribe newly-launched product

Evoke Pharma Announces Positive Findings from GIMOTI™ Market Research Study

Investors need to pay close attention to Evoke Pharma (EVOK) stock based on the movements in the options market lately.

Do Options Traders Know Something About Evoke Pharma (EVOK) Stock We Don't?

Evoke Pharma Reports Third Quarter 2020 Financial Results

Product launch provides healthcare providers a novel treatment approach for patients suffering from symptoms of acute and recurrent diabetic gastroparesis Product launch provides healthcare providers a novel treatment approach for patients suffering from symptoms of acute and recurrent diabetic gastroparesis

Evoke and EVERSANA Announce Commercial Launch of Gimoti™

SOLANA BEACH, Calif., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer R.Ph., President and Chief Executive Officer, and Matt D’Onofrio, Chief Business Officer, are scheduled to participate virtually in the H.C. Wainwright 22nd Annual Global Investment Conference taking place September 14 – September 16, 2020.

Evoke Pharma to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference

Gimoti commercial launch on track for the fourth quarter of 2020 Gimoti commercial launch on track for the fourth quarter of 2020

Evoke Pharma and EVERSANA Announce the Appointment of Christopher Quesenberry as Chief Commercial Officer for Gimoti™

Preparing for commercial launch of GIMOTI™ in 4Q 2020 Preparing for commercial launch of GIMOTI™ in 4Q 2020

News for Evoke Pharma Stock (EVOK)